108 related articles for article (PubMed ID: 19058494)
1. [Immunology and BCG therapeutics].
Sánchez Olivas MA; Valencia Zavala MP; Montes Montes J; Sánchez Olivas JA; Flores Méndez I
Rev Alerg Mex; 2008; 55(4):153-63. PubMed ID: 19058494
[TBL] [Abstract][Full Text] [Related]
2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
5. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin in the Treatment of Tuberculosis and Bladder Cancer: Clinical Use and Immunologic Response. Reports of a workshop. Toronto, Canada, 11-13 July 1994.
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S59-121. PubMed ID: 11153467
[No Abstract] [Full Text] [Related]
7. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
Böhle A; Brandau S
J Urol; 2003 Sep; 170(3):964-9. PubMed ID: 12913751
[TBL] [Abstract][Full Text] [Related]
8. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
[TBL] [Abstract][Full Text] [Related]
9. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
10. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
11. Defining bacillus Calmette-Guerin refractory superficial bladder tumors.
Herr HW; Dalbagni G
J Urol; 2003 May; 169(5):1706-8. PubMed ID: 12686813
[TBL] [Abstract][Full Text] [Related]
12. Strategies for optimizing bacillus Calmette-Guérin.
Shah JB; Kamat AM
Urol Clin North Am; 2013 May; 40(2):211-8. PubMed ID: 23540779
[TBL] [Abstract][Full Text] [Related]
13. Management of BCG failures in superficial bladder cancer: a review.
Witjes JA
Eur Urol; 2006 May; 49(5):790-7. PubMed ID: 16464532
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with bacillus Calmette-Guerin in patients with superficial bladder cancer.
Swibold LK
Urol Nurs; 1999 Mar; 19(1):38-41. PubMed ID: 10373991
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
Alexandroff AB; Nicholson S; Patel PM; Jackson AM
Immunotherapy; 2010 Jul; 2(4):551-60. PubMed ID: 20636008
[TBL] [Abstract][Full Text] [Related]
16. [Systemic BCG reactions after intravesical BCG therapy. A report of four cases].
Sfaxi M; Langar H; Ouni A; Riahi Y; El Aidli S; Daghfous R; Ben Abdeladhim A; Chébil M
Therapie; 2008; 63(1):43-7. PubMed ID: 18387275
[TBL] [Abstract][Full Text] [Related]
17. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
[TBL] [Abstract][Full Text] [Related]
18. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
Vaage J
Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
[TBL] [Abstract][Full Text] [Related]
19. Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin.
O'Donnell M
J Urol; 2006 Apr; 175(4):1197-8. PubMed ID: 16515958
[No Abstract] [Full Text] [Related]
20. Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer.
Rink M; Xylinas E; Babjuk M; Pycha A; Karakiewicz PI; Novara G; Dahlem R; Shariat SF
Eur Urol; 2012 Dec; 62(6):1204-6. PubMed ID: 22980442
[No Abstract] [Full Text] [Related]
[Next] [New Search]